Ref. Ares(2021)1311067 - 17/02/2021
Ref. Ares(2021)1400307 - 22/02/2021
Meeting with Medicines for Europe
Meeting date and place
Meeting held on 14/12/2020 11:01 in Brussels
Participating organisation(s) & representative(s)
- MEDICINES FOR
[Art. 4.1 (b)]
[Art. 4.1 (b)]
Participant,
EUROPE (TRN: 48325781850-28)
[Art. 4.1 (b)]
- - MEDICINES FOR EUROPE (TRN: 48325781850-28)
Participant,
Participant,
- - MEDICINES FOR EUROPE (TRN: 48325781850-28)
[Art. 4.1 (b)]
Requester,
- MEDICINES FOR EUROPE (TRN: 48325781850-28)
[Art. 4.1 (b)]
[Art. 4.1 (b)]
Participant,
Main issues discussed
Medicines for Europe outlined that generic medicines account for 67% of the volume of prescription medicines in Europe.
Medicines for Europe underlined the importance of global supply chains for the sector, the role of the EU as supplier of medicines and
active ingredients to third countries, and presented lessons learned from the COVID-19 pandemic.
Medicines for Europe expressed interest in the recently adopted EU Pharmaceuticals Strategy and in the Trade and Health initiative,
stressing the importance for the sector to avoid the imposition of trade restrictive measures globally that would have negative impact on
supply chains.
Medicines for Europe explained the key importance of well-performing procurement mechanisms to achieve a sustainable and competitive
market for the sector.
Directorate or unit
TRADE E/3
Internal participants
[Art. 4.1 (b)]
TRADE E/3
@ec.europa.eu)
[Art. 4.1 (b)]
Participant,
TRADE E/3
@ec.europa.eu)
[Art. 4.1 (b)]
[Art. 4.1 (b)]
Participant,
Notetaker,
TRADE D/1
@ec.europa.eu)
[Art. 4.1 (b)]
[Art. 4.1 (b)]
Participant,
Author(s) of minutes
[Art. 4.1 (b)]
Validator and validation date
validated the minutes on 17/02/2021 09:25
[Art. 4.1 (b)]
Minutes generated by EMT (Id:TRADE/1821)
Page 1 of 1